Eli Lilly and Company (NYSE:LLY) Given New $1,133.00 Price Target at Bank of America

Bank of America has lowered its price target for Eli Lilly and Company to $1,133.00 from $1,294.00, while maintaining a “buy” rating, indicating a potential upside of 17.39%. This adjustment comes despite Eli Lilly’s strong Q1 earnings beat and raised full-year guidance, driven by the success of its GLP-1 drugs. Analyst sentiment for the company remains largely positive, with a “Moderate Buy” consensus rating and an average price target of $1,212.96, though risks like competitor oral GLP-1 rollouts and pricing pressures are noted.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin